Search results

The purpose of this note is to provide a general overview of various key aspects of planning and structuring an M&A transaction involving a target active in the Russian healthcare sector.  In this briefing we address typical features and potential pitfalls...

Mit unserer heutigen Ausgabe des "Newsflash" nehmen wir Bezug auf einen Beschluss des Oberlandesgerichts Düsseldorf vom 11.01.2012, wonach es zulässig sein kann, Rabattvereinbarungen ohne europaweite Ausschreibung zu vergeben. Voraussetzung...

In the first of two articles on the impact on pharmaceutical companies of China's antitrust regime, we focus on the changing shape of merger control review.

Selected regulatory changes April – June 2011 (English & Chinese)

In this second of two articles exploring the impact of China's antitrust regime on the pharmaceutical industry, we consider in more detail how the day-to-day operations of pharmaceutical companies are affected by China's competition regime, and highlight...

China's pricing regulator, the National Development and Reform Commission ("NDRC"), recently published an announcement (the "NDRC Announcement") ranking the pharmaceutical sector as the worst offender for pricing violations in 2010...

Foreign companies doing business in China's life sciences sector must pay special attention to the protection and enforcement regime in China of intellectual property (IP), oftentimes their most valuable asset. This article provides an overview of key...

The attached memorandum sets out a summary of certain legal aspects which should be taken into account when doing business in Angola. It is not intended to be exhaustive and is provided for information purposes only. The memorandum addresses the following: general...

The United States Court of Appeals for the Eighth Circuit recently affirmed a lower court decision finding that two drugs were not necessarily in the same relevant product market for antitrust purposes, even though the drugs were two alternatives used to treat...